DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Laurent Peyrin-Biroulet  ¹     Millie Long  ²     Britta Siegmund  ³     Peter Irving  ⁴     Freddy Caldera  ⁵     Anjali Jain  ⁶     Hsiuanlin Wu  ⁶     Mark Osterman  ⁶     David T. Rubin  ⁷     Bincy P. Abraham  ^8    
1 Nancy University Hospital, Nancy, France
² UNC Chapel Hill, Chapel Hill, United States
³ Charité – Universitätsmedizin Berlin, Berlin, Germany
⁴ Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
⁵ University of Wisconsin School of Medicine and Public Health, Madison, United States
⁶ Bristol Myers Squibb, Princeton, United States
⁷ University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States
⁸ Houston Methodist-Weill Cornell, Houston, United States

Topic
IBD

Session
Targeting immune cell trafficking in IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)